Sacubitril-Valsartan May Be Cost-Effective Option in HFrEF

Share this content:
Sacubitril-Valsartan May Be Cost-Effective Option in HFrEF
Sacubitril-Valsartan May Be Cost-Effective Option in HFrEF

THURSDAY, April 7, 2016 (HealthDay News) -- For patients with heart failure with reduced ejection fraction (HFrEF), sacubitril-valsartan may be cost-effective, depending on the willingness-to-pay threshold, according to a study published online March 30 in JACC: Heart Failure.

Jordan B. King, Pharm.D., from the University of Utah College of Pharmacy in Salt Lake City, and colleagues examined the cost-effectiveness of sacubitril-valsartan compared with enalapril for treatment of HFrEF. Costs, effects, and cost-effectiveness of the therapies were estimated using a Markov model. At model entry, patients were 60 years of age, and were modeled over 40 years from the perspective of a third-party payer.

The researchers found that over a lifetime, compared with enalapril, sacubitril-valsartan was more costly ($60,361 versus $21,758) and more effective (6.49 versus 5.74 quality-adjusted life-years [QALYs]) in the base case. The cost-effectiveness of sacubitril-valsartan varied with treatment duration, from $249,411 per QALY at three years to $50,959 per QALY gained over a lifetime.

"Sacubitril-valsartan may be a cost-effective treatment option depending on the willingness-to-pay threshold," the authors write. "Future investigations should incorporate real-world evidence with sacubitril-valsartan to further inform decision making."

Several authors disclosed financial ties to Amgen.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease


More in Home

FDA Approves 'Artificial Pancreas' for Type 1 Diabetes

FDA Approves 'Artificial Pancreas' for Type 1 Diabetes

MiniMed 670G hybrid closed loop system automatically monitors glucose, delivers insulin

More Evidence HPV Vaccine Protects Against Cervical Cancer

More Evidence HPV Vaccine Protects Against Cervical Cancer

Protection appears to occur even when only one or two of the recommended doses are given

Prescribed NSAIDs Tied to Higher Heart Failure Risk

Prescribed NSAIDs Tied to Higher Heart Failure Risk

Study of millions of health records suggests an association

is free, fast, and customized just for you!

Already a member?

Sign In Now »